Background and objectives: In hemodialysis patients, both hemoglobin variability and targeting normalization of hemoglobin may have adverse consequences. There are few data on epoetin management in patients achieving high hemoglobin levels.
rythropoietin deficiency is an important contributor to anemia in individuals with chronic kidney disease (CKD) (1) . Epoetin therapy was approved for the treatment of anemia of CKD based on data showing decreased transfusion requirements and improved health-related quality of life in dialysis patients with severe anemia (2); subsequent small studies showed similar benefits (3) (4) (5) (6) (7) (8) . Notably, many of these benefits were not seen in more recent trials targeting normalization of hemoglobin in late-stage CKD and dialysis patients (9, 10) , with several larger trials raising substantial concerns regarding either a lack of benefit or potential harms associated with targeting hemoglobin "normalization" (to Ͼ13 g/dl) (10 -13) . These concerns, when balanced against cohort data showing potential risks associated with marked hemoglobin variability (14, 15) , result in substantial uncertainty regarding the optimal anemia management strategy in dialysis (16) .
In April 2006, perhaps reflecting a desire to minimize hemoglobin variability, the Center for Medicare and Medicaid Services (CMS) implemented a new EPO Monitoring Policy allowing reimbursement of continued epoetin dosing at hemoglobin levels Ͼ13 g/dl with a mandatory 25% reduction in total epoetin administered for patients exceeding this level (17) . This policy change mirrored concurrent recommendations from the National Kidney Foundation's Kidney Disease Outcome Quality Initiative (KDOQI), which had been updated to eliminate an upper hemoglobin target level. After publication of the Correction of Hemoglobin Outcomes in Renal Insufficiency (CHOIR) study and the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) study, KDOQI revisited the anemia guideline, recommending a target hemoglobin level of 11 to 12 g/dl (18) . This recommendation differs from the U.S. Food and Drug Adminstration (FDA) and CMS, both of which now recommend a target of 10 to 12 g/dl (19) .
A prior cross-sectional analysis by our group using Dialysis Clinic Inc (DCI) data showed that reduction versus discontinuation of epoetin at a hemoglobin level of 13 g/dl resulted in significantly more hemoglobin levels Ͼ13 g/dl, fewer levels between 11 and 12.9 g/dl, and no difference in the proportion of levels Ͻ11 g/dl each month (20) . This study builds on this observation by evaluating longitudinal changes in hemoglobin levels in individual hemodialysis patients with hemoglobin Ն 13 g/dl treated with reduction or discontinuation of epoetin to help inform best management of high hemoglobin levels in these individuals. Using DCI data and taking advantage of a change in epoetin dosing patterns in response to the CMS policy change in 2006, we evaluated 2-month nadir hemoglobin levels after reduction or discontinuation of epoetin after achieving hemoglobin Ն13 g/dl and explored individual patient factors associated with more precipitous drops in hemoglobin level.
Materials and Methods

Subjects
Patients receiving hemodialysis in DCI units between October 2005 and September 2006 with hemoglobin levels Ն13 g/dl were eligible; each patient could be included only once. To maximize the likelihood that changes in hemoglobin were driven by anemia management strategies rather than acute illness or changes in epoetin dose motivated by missed sessions, we excluded individuals who did not have three in-center hemodialysis treatments the week before measuring the hemoglobin levels Ն13 g/dl and individuals who did not have at least 20 in-center hemodialysis treatments over the subsequent 2 months after the dose change. Because epoetin reduction was the favored strategy for only 7 months at DCI, we chose a follow-up of 2 months to balance maximizing our available data with the knowledge that red blood cell survival in hemodialysis patients may be only 20 to 35 days (1,21).
Epoetin Dosing
In 2004, DCI introduced a computer-assisted EPO dosing algorithm (22) . Use of this algorithm was optional and, through 2007, was used by a minority of DCI units. Units not using the algorithm determined epoetin dose manually or pursuant to local paper-based protocols. Through April 30, 2006 , the algorithm mandated discontinuation of epoetin at hemoglobin Ն13 g/dl. A revised algorithm, implemented on May 1, 2006, recommended a dose reduction starting at a minimum of 25% that could increase to as high as 75% over the course of a month for sustained hemoglobin values Ͼ13 g/dl. Iron was dosed at the discretion of the treating physician. All patients received erythropoietin alfa (Epogen; Amgen Inc, Thousand Oaks, CA) by intravenous administration during dialysis; the dose administered was recorded at each treatment. For patients to be classified as "discontinuation," they had to receive epoetin the week before reaching hemoglobin levels Ն13 g/dl and could not receive any epoetin for at least a week after a measurement of Ն13 g/dl; similarly, to be classified as "reduction," patients needed to be receiving epoetin in the week leading up to the measurement with a reduction in epoetin dose of 20 to 30% in the ensuing week (to account for variability introduced by rounding).
Covariates
Demographic variables were obtained from the DCI database. Frequency of hemoglobin measurement was at the discretion of the individual dialysis unit, typically occurring once to twice monthly; in patients where epoetin was discontinued by protocol, hemoglobin was assessed weekly or biweekly to facilitate timely reinitiation. Nearly 97% of hemoglobin levels were measured at DCI's central laboratory in Nashville, TN. The remainder were measured at local laboratories. Most other measures occurred at DCI's central laboratory, including ferritin, transferrin saturation, serum albumin (bromocresol green), intact parathyroid hormone (PTH, Diasorin assay), and pre-and postdialysis urea nitrogen levels to determine single pool Kt/V. To minimize heterogeneity associated with laboratory variability, baseline values for covariates were determined using the 2-month average of ferritin, transferrin saturation, albumin, and Kt/V. PTH was generally measured quarterly, with the most proximate measure used.
Outcomes
The primary outcome was nadir hemoglobin within 2 months of a dose change for hemoglobin Ն13 g/dl, with multivariable analyses assessing the impact of baseline epoetin dose (before dose reduction or discontinuation) on subsequent nadir hemoglobin levels in each patient, as well as other variables that were associated with nadir hemoglobin Ͻ10 g/dl. We also examined the proportion of individuals maintaining hemoglobin levels Ͼ12 g/dl after 2 months.
Statistical Analyses
Two-sample t tests and the Wilcoxon rank test were used for comparisons of continuous variables. Pearson 2 tests were used for categorical variables. Logistic regression was used to determine variables associated with nadir hemoglobin levels Ͻ10 and Ͼ12 g/dl. Candidate variables for multivariable regression models included age, gender, race, transferrin saturation, ferritin, intact PTH, time on dialysis, total number of hemoglobin measurements, weight-adjusted dose of epoetin administered the week before reaching hemoglobin levels Ն13 g/dl, serum albumin level, spKt/V, and hemoglobin level at the time of epoetin dose change. Stepwise regression was used, with variables retained at P Ͻ 0.05. A sensitivity analysis limited the study population to patients receiving hemodialysis in units using a computer-assisted protocol. SAS version 9.1 (SAS Institute, Cary, NC) was used for all analyses.
Results
Baseline Characteristics
There were 2789 patients in whom epoetin was discontinued and 754 patients in whom epoetin was reduced in response to hemoglobin Ն13 g/dl. Individuals in whom epoetin was discontinued were younger, were more likely to be African American, had higher hemoglobin levels at the time of dose change, and had higher ferritin and iron saturation during the ensuing 2 months. The total dose of epoetin given during the 2 months after dose change was significantly higher in individuals treated with a reduction strategy ( Table 1) .
Comparison of Treatment Strategies
Discontinuation of epoetin was associated with more patients achieving nadir hemoglobin within the range specified by either the FDA (10 to 12 g/dl) or KDOQI guidelines (11 to 12 g/dl), whereas the reduction strategy was associated with more frequent 2-month nadir levels Ͼ12 g/dl (Table 2 and Figure 1) . Similar results were seen after stratifying by the dose of epoetin received the week before reaching hemoglobin levels Ն13 g/dl (Table 3) .
A total of 228 patients (6.4%) had a hemoglobin nadir Ͻ10 g/dl, including 201 (7.2%) who had epoetin discontinued and 27 (3.6%) who had the dose reduced. In univariate analyses, individuals with nadir hemoglobin Ͻ10 g/dl were younger, more often women, and more likely to have discontinued epoetin (Table 4) . In multivariable models, discontinuation of epoetin remained associated with increased likelihood of nadir hemoglobin Ͻ10 g/dl (Table 5 ). In analyses examining high nadir hemoglobin levels within 2 mo of an epoetin prescription change, reduction rather than discontinuation of epoetin, older age, higher serum albumin, more frequent hemoglobin measurement during this time period, lower Kt/V, lower ferritin, and higher baseline epoetin dose per kilogram body weight were associated with nadir hemoglobin level Ͼ12 g/dl (Table 5 ).
In the subgroup analysis of 807 patients whose epoetin dose was managed using the computer-assisted protocol, 546 discontinued epoetin and 261 had a reduced dose. The discontinuation strategy was associated with more patients with nadir hemoglobin level Ͻ10 g/dl [38 (7.0%) versus 11 (4.2%)] and more patients within contemporary target ranges proposed by the FDA (10 to 12 g/dl) and KDOQI (11 to 12 g/dl). The proportion of patients with nadir hemoglobin level Ͼ12 g/dl was higher with the reduction strategy [204 (37.4%) versus 186 (71.3%)]. Results of multivariable models examining this subgroup were similar to primary analyses (Table 5 ).
Discussion
In this study, we explored the effects of discontinuing versus reducing epoetin dose in dialysis patients who achieve a high hemoglobin level, and we showed that discontinuation results in less use of epoetin and more frequent hemoglobin levels within the KDOQI and FDA recommended range; however, discontinuation of epoetin is also associated with more frequent Continuous data are mean Ϯ SD or median (25th to 75th percentile). Transferrin saturation is in %, ferritin in mg/dl, albumin and hemoglobin in g/dl, and intact parathyroid hormone (PTH) in pg/ml. Total Epo administered is per 1000 IU. nadir hemoglobin levels below the current target of 10 g/dl and the 2007 KDOQI target of 11 g/dl. Notably, although this is a statistically significant difference, discontinuation of epoetin resulted in only a 3.6% greater incidence of very low hemoglobin levels within 2 months of this therapeutic change. There are several important findings arising from this study. First, we provide information about the balance required between epoetin administration and achievement of target hemoglobin levels. This may have multiple consequences, including (1) increased health benefits for patients if specific hemoglobin levels rather than targets are truly associated with improved patient outcomes (23, 24) ; (2) facilitating achievement of CMS quality performance guidelines, which, at the current time, evaluate dialysis units on their ability to maintain hemoglobin levels between 10 and 12 g/dl (19) ; and (3) generation of information necessary to determine cost-effective epoetin dosing strategies. For dialysis providers, maximizing results while minimizing costs will assume greater importance after the im- Continuous data are mean Ϯ SD or median (25th to 75th percentile). Transferrin saturation is in %, ferritin in mg/dl, albumin and hemoglobin in g/dl, and intact parathyroid hormone (PTH) in pg/ml. Sessions without Epo reflects only individuals in whom Epoetin was discontinued. Total Epo administered is per 1000 IU.
plementation of an expanded prospective payment system that will include erythropoiesis-stimulating agents (25) . Assuming acquisition costs of epoetin of approximately $9 dollars per 1000 units (26) , the potential additional cost associated with use of a reduction versus discontinuation strategy when an individual's hemoglobin level reaches 13 g/dl is $39,735 over a 2-month period for every hundred patients with high hemoglobin level at baseline. The benefit associated with this expenditure is that 3.6 individuals who would otherwise have had a nadir hemoglobin Ͻ10 g/dl will not reach this threshold within 2 months. Further study is required to elucidate whether potential harms associated with hemoglobin cycling make this expenditure cost effective.
Second, we explored factors contributing to a more precipitous drop in hemoglobin after reaching levels of 13 g/dl, because knowledge of these factors may facilitate development of individualized epoetin dosing strategies. In multivariable analyses, both lower serum albumin level (likely identifying either poor nutrition or an inflammatory state) and elevated serum ferritin level (likely identifying an inflammatory state) were associated with a higher likelihood of achieving a nadir hemoglobin level Ͻ10 g/dl. Additionally, individuals with a higher baseline dose of epoetin were more likely to have a precipitous drop, again likely consistent with pre-existing inflammation and/or bone marrow resistance to epoetin. Finally age had an inverse correlation with a decrease in hemoglobin in our study, such that older individuals were less likely to have a precipitous decline. Although the reason for this result is uncertain, it has been noted elsewhere (27) .
Concerns over potential adverse effects associated with abrupt discontinuation of epoetin are rooted in red blood cell physiology. Erythropoietin maintains hemoglobin levels through two mechanisms. First, it prevents the apoptosis of early bone marrow red blood cell progenitors while stimulating the proliferation of these cells (28) . Second, it prevents the selective hemolysis of the youngest circulating red blood cells, a process called neocytolysis, whereby the body adapts to excessive red blood cell mass by decreasing the circulating number of red blood cells (29) . If neocytolysis is an important factor in dialysis patients, abrupt discontinuation of epoetin could produce an acute drop in hemoglobin levels. However, the significance of neocytolysis in dialysis patients remains uncertain, because erythropoietin deficiency is relative rather than absolute in this population (30 -32) ; accordingly, other factors may influence whether neocytolysis occurs in individual dialysis patients (33, 34) .
Our findings are concordant with other studies. Berns et al. (27) described a direct correlation among mean corpuscular volume, ferritin level, and hemoglobin variability, whereas albumin and older age had an inverse correlation with hemoglobin variability. Similar to our findings, other laboratory parameters in the study by Berns et al., including iPTH and Kt/V, were not significantly correlated with hemoglobin variability in their study. In a follow-up study, Fishbane and Berns (35) noted that factors associated with drops in hemoglobin included both holding and reducing the baseline dose of epoetin, intercurrent infection, and discontinuation of iron. Similarly, Ebben et al. (14) found an association between hemoglobin variability and the number of comorbid conditions. This study expands on a prior analysis by our group that showed a benefit on a dialysis provider level associated with discontinuation of epoetin at higher levels (20) . In that study, there was no significant difference in the number of patients with a hemoglobin level Ͻ10 g/dl in any given month, whereas in this study, the discontinuation protocol was associated with significantly more patients with low nadir hemoglobin levels. This apparent discrepancy reflects the fact that this study population was limited to the small subset of patients in whom hemoglobin of 13 g/dl was reached, whereas the prior study included the entire dialysis population potentially affected by the protocol at any given time. Accordingly, although the twofold rise in individuals with nadir hemoglobin level Ͻ10 g/dl seems substantial, the total number of patients with this drop in hemoglobin level represents a very small proportion of the entire dialysis population. Results for the primary and subgroup analyses each reflect two separate models. Odds ratio represents each 20 IU/kg increase in epoetin dose. spKt/V was not included in models examining hemoglobin Ͻ10 g/dl. All variables significant in the primary analyses were included in the subgroup analyses.
a The average per session dose of epoetin given the week before achieving hemoglobin Ն13 g/dl.
There are several limitations to this study. First, detailed information about other anemia management strategies, including iron administration, was not available and may vary among dialysis units. We addressed this limitation by performing analyses isolated to the subset of units that were managed with the computer-assisted protocol throughout the study period, with the supposition that, within unit, iron strategies were not likely to substantially change over the course of the 14-month study period; these subgroup analyses showed similar results. Second, several baseline characteristics differed across management strategies. We adjusted for these differences in multivariable models and noted that similar covariates as described by others were associated with a decline in hemoglobin levels. Third, comorbidities that may affect hemoglobin level, including hospitalization, bleeding episodes, and infection, were not available for analysis. We minimized this effect by excluding all individuals who were missing more than three monthly dialysis sessions in the 2-month follow-up period. Additionally, we limited hemoglobin ascertainment to 2 months after epoetin dose change; whereas this may result in missing a more gradual achievement of low nadir hemoglobin, we felt that extant data on neocytolysis supported the proposition that a more rapid decline in the setting of abrupt epoetin discontinuation would be expected.
Our study also has substantial strengths. We analyzed a fairly large and representative dataset that is generalizable to real-world practices. Additionally, reflecting conservative epoetin utilization practices within DCI (36), we describe a population with relatively low utilization of epoetin; this is important, because it is likely that, moving forward, industry-wide epoetin utilization will decrease. Finally, we are able to incorporate multiple demographic characteristics and baseline iron status into multivariable models assessing associates of hemoglobin decline.
Conclusions
Once a maintenance hemodialysis patient achieves a hemoglobin level Ն13 g/dl, an epoetin discontinuation strategy is associated with a higher probability of reaching the hemoglobin target range stipulated by KDOQI or FDA guidelines within 2 months compared with a reduction strategy. However, a discontinuation strategy is associated with a higher likelihood of a low nadir hemoglobin level, whereas a reduction strategy is associated with significantly increased time at higher than desired hemoglobin levels. Reflecting current limitations in knowledge, it is possible that both strategies may be associated with adverse outcomes. This study provides important data on factors that are associated with more precipitous decline in hemoglobin levels and may enable cost-benefit analyses that will facilitate dialysis practices in years to come.
